drugset
drugset / Trial / NCT07297693

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

NCT07297693 ↗

Phase 1 Not yet recruiting 60 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.

Timeline

Start
2025-12-19
Primary completion
2026-03-25
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1306 Unknown — Oral
Subject HIP2503 Unknown — Oral

Indications

No indication recorded.